The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Montelukast Intermediate Market Research Report 2024
Synopsis
Montelukast Intermediate is a leukotriene receptor antagonist (LTRA)
The global Montelukast Intermediate market was valued at US$ 4998.7 million in 2023 and is anticipated to reach US$ 6108.1 million by 2030, witnessing a CAGR of 2.5% during the forecast period 2024-2030.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines. Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report aims to provide a comprehensive presentation of the global market for Montelukast Intermediate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Montelukast Intermediate.
Report Scope
The Montelukast Intermediate market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Montelukast Intermediate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Montelukast Intermediate manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
VIVAN Life Sciences
P.G. Shah & Co.
Manus Aktteva Biopharma
Ortin Laboratories
Segment by Type
GMP
Non-GMP
Segment by Application
Asthma
Allergic Rhinitis
Bronchospasm
Urticaria
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Montelukast Intermediate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Montelukast Intermediate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Montelukast Intermediate is a leukotriene receptor antagonist (LTRA)
The global Montelukast Intermediate market was valued at US$ 4998.7 million in 2023 and is anticipated to reach US$ 6108.1 million by 2030, witnessing a CAGR of 2.5% during the forecast period 2024-2030.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines. Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report aims to provide a comprehensive presentation of the global market for Montelukast Intermediate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Montelukast Intermediate.
Report Scope
The Montelukast Intermediate market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Montelukast Intermediate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Montelukast Intermediate manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
VIVAN Life Sciences
P.G. Shah & Co.
Manus Aktteva Biopharma
Ortin Laboratories
Segment by Type
GMP
Non-GMP
Segment by Application
Asthma
Allergic Rhinitis
Bronchospasm
Urticaria
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Montelukast Intermediate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Montelukast Intermediate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Montelukast Intermediate Market Overview
1.1 Product Overview and Scope of Montelukast Intermediate
1.2 Montelukast Intermediate Segment by Type
1.2.1 Global Montelukast Intermediate Market Value Comparison by Type (2024-2030)
1.2.2 GMP
1.2.3 Non-GMP
1.3 Montelukast Intermediate Segment by Application
1.3.1 Global Montelukast Intermediate Market Value by Application: (2024-2030)
1.3.2 Asthma
1.3.3 Allergic Rhinitis
1.3.4 Bronchospasm
1.3.5 Urticaria
1.4 Global Montelukast Intermediate Market Size Estimates and Forecasts
1.4.1 Global Montelukast Intermediate Revenue 2019-2030
1.4.2 Global Montelukast Intermediate Sales 2019-2030
1.4.3 Global Montelukast Intermediate Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Montelukast Intermediate Market Competition by Manufacturers
2.1 Global Montelukast Intermediate Sales Market Share by Manufacturers (2019-2024)
2.2 Global Montelukast Intermediate Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Montelukast Intermediate Average Price by Manufacturers (2019-2024)
2.4 Global Montelukast Intermediate Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Montelukast Intermediate, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Montelukast Intermediate, Product Type & Application
2.7 Montelukast Intermediate Market Competitive Situation and Trends
2.7.1 Montelukast Intermediate Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Montelukast Intermediate Players Market Share by Revenue
2.7.3 Global Montelukast Intermediate Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Montelukast Intermediate Retrospective Market Scenario by Region
3.1 Global Montelukast Intermediate Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Montelukast Intermediate Global Montelukast Intermediate Sales by Region: 2019-2030
3.2.1 Global Montelukast Intermediate Sales by Region: 2019-2024
3.2.2 Global Montelukast Intermediate Sales by Region: 2025-2030
3.3 Global Montelukast Intermediate Global Montelukast Intermediate Revenue by Region: 2019-2030
3.3.1 Global Montelukast Intermediate Revenue by Region: 2019-2024
3.3.2 Global Montelukast Intermediate Revenue by Region: 2025-2030
3.4 North America Montelukast Intermediate Market Facts & Figures by Country
3.4.1 North America Montelukast Intermediate Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Montelukast Intermediate Sales by Country (2019-2030)
3.4.3 North America Montelukast Intermediate Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Montelukast Intermediate Market Facts & Figures by Country
3.5.1 Europe Montelukast Intermediate Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Montelukast Intermediate Sales by Country (2019-2030)
3.5.3 Europe Montelukast Intermediate Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Montelukast Intermediate Market Facts & Figures by Country
3.6.1 Asia Pacific Montelukast Intermediate Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Montelukast Intermediate Sales by Country (2019-2030)
3.6.3 Asia Pacific Montelukast Intermediate Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Montelukast Intermediate Market Facts & Figures by Country
3.7.1 Latin America Montelukast Intermediate Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Montelukast Intermediate Sales by Country (2019-2030)
3.7.3 Latin America Montelukast Intermediate Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Montelukast Intermediate Market Facts & Figures by Country
3.8.1 Middle East and Africa Montelukast Intermediate Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Montelukast Intermediate Sales by Country (2019-2030)
3.8.3 Middle East and Africa Montelukast Intermediate Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Montelukast Intermediate Sales by Type (2019-2030)
4.1.1 Global Montelukast Intermediate Sales by Type (2019-2024)
4.1.2 Global Montelukast Intermediate Sales by Type (2025-2030)
4.1.3 Global Montelukast Intermediate Sales Market Share by Type (2019-2030)
4.2 Global Montelukast Intermediate Revenue by Type (2019-2030)
4.2.1 Global Montelukast Intermediate Revenue by Type (2019-2024)
4.2.2 Global Montelukast Intermediate Revenue by Type (2025-2030)
4.2.3 Global Montelukast Intermediate Revenue Market Share by Type (2019-2030)
4.3 Global Montelukast Intermediate Price by Type (2019-2030)
5 Segment by Application
5.1 Global Montelukast Intermediate Sales by Application (2019-2030)
5.1.1 Global Montelukast Intermediate Sales by Application (2019-2024)
5.1.2 Global Montelukast Intermediate Sales by Application (2025-2030)
5.1.3 Global Montelukast Intermediate Sales Market Share by Application (2019-2030)
5.2 Global Montelukast Intermediate Revenue by Application (2019-2030)
5.2.1 Global Montelukast Intermediate Revenue by Application (2019-2024)
5.2.2 Global Montelukast Intermediate Revenue by Application (2025-2030)
5.2.3 Global Montelukast Intermediate Revenue Market Share by Application (2019-2030)
5.3 Global Montelukast Intermediate Price by Application (2019-2030)
6 Key Companies Profiled
6.1 VIVAN Life Sciences
6.1.1 VIVAN Life Sciences Corporation Information
6.1.2 VIVAN Life Sciences Description and Business Overview
6.1.3 VIVAN Life Sciences Montelukast Intermediate Sales, Revenue and Gross Margin (2019-2024)
6.1.4 VIVAN Life Sciences Montelukast Intermediate Product Portfolio
6.1.5 VIVAN Life Sciences Recent Developments/Updates
6.2 P.G. Shah & Co.
6.2.1 P.G. Shah & Co. Corporation Information
6.2.2 P.G. Shah & Co. Description and Business Overview
6.2.3 P.G. Shah & Co. Montelukast Intermediate Sales, Revenue and Gross Margin (2019-2024)
6.2.4 P.G. Shah & Co. Montelukast Intermediate Product Portfolio
6.2.5 P.G. Shah & Co. Recent Developments/Updates
6.3 Manus Aktteva Biopharma
6.3.1 Manus Aktteva Biopharma Corporation Information
6.3.2 Manus Aktteva Biopharma Description and Business Overview
6.3.3 Manus Aktteva Biopharma Montelukast Intermediate Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Manus Aktteva Biopharma Montelukast Intermediate Product Portfolio
6.3.5 Manus Aktteva Biopharma Recent Developments/Updates
6.4 Ortin Laboratories
6.4.1 Ortin Laboratories Corporation Information
6.4.2 Ortin Laboratories Description and Business Overview
6.4.3 Ortin Laboratories Montelukast Intermediate Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Ortin Laboratories Montelukast Intermediate Product Portfolio
6.4.5 Ortin Laboratories Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Montelukast Intermediate Industry Chain Analysis
7.2 Montelukast Intermediate Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Montelukast Intermediate Production Mode & Process
7.4 Montelukast Intermediate Sales and Marketing
7.4.1 Montelukast Intermediate Sales Channels
7.4.2 Montelukast Intermediate Distributors
7.5 Montelukast Intermediate Customers
8 Montelukast Intermediate Market Dynamics
8.1 Montelukast Intermediate Industry Trends
8.2 Montelukast Intermediate Market Drivers
8.3 Montelukast Intermediate Market Challenges
8.4 Montelukast Intermediate Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
